A Practical Security and Access Control Checklist for Clinical Trial Data Workspaces
Why the access model matters before the first dataset lands
Clinical trial data does not stay in one place for long. A single study can involve CRF data, SDTM and ADaM datasets, define.xml, lab data, protocols, SAPs and TFL outputs. A workspace is useful when it brings those materials together, but that convenience creates a test: can the study team see what they need without exposing what they should not see? Security and access control are not back-office details. They shape how data managers review forms, how biostatisticians trace a dataset back to a data cut, and how a study lead handles a question about a blinded record.
The checklist below is deliberately practical. It focuses on controls that a study team can ask about in a demo and look for in a workspace. The aim is not to turn every reviewer into a security specialist. It is to make sure the important questions are asked before a study becomes dependent on a new environment.
Verify account boundaries and non-destructive retention
Start with the boundary around the customer. A strong setup puts each customer in a separate AWS account, with its own database and storage. That separation is easy to describe and worth verifying in concrete terms. Ask where the study’s database lives, where files are stored, and whether another customer’s environment shares those resources. The answer should be clear enough for a data manager and a biostatistician to understand without translating a diagram.
Next, ask what happens when a record changes. The safer model is non-destructive: nothing is deleted, records are retired or superseded, and every file revision is kept. Each data cut is kept as its own version with a checksum. This matters when a team compares cuts, reviews a corrected dataset, or needs to explain why an earlier output differs from a later one. A workspace that overwrites files may look tidy, but it removes the evidence a study team needs when questions arise.
The audit trail should be append-only. Changes to membership, roles, unblinding and records should be written to a log that ordinary users cannot rewrite or erase. Ask whether the log is append-only in practice, not just in name. Who can view it? Can an administrator delete an entry? Is the trail tied to the action and the record? When you review a clinical trial data management platform, ask for a walkthrough of these controls with a real study record, including a superseded file and a changed role.
Map study-level roles and unblinding permissions
Access should follow the study, not the whole platform. In a well-scoped workspace, people see only the studies they belong to, with roles such as viewer, collaborator or owner. The role names are useful, but the permission matrix behind them matters more. Ask what each role can do: who can upload a data cut, who can attach an issue to a record, who can change membership, and who can retire a record. Then ask whether those permissions are assigned per study or inherited across the entire account.
Collaboration features deserve the same scrutiny. Notes and issues can be attached to the exact form, field, row or document page they concern, which is useful because context travels with the comment. But ask where that note is visible. Can someone outside the study see it? Does a note on an unblinded record inherit the unblinding grant? The access model should cover discussions as well as files, otherwise a comment thread can become an unintended side channel.
Blinding needs its own test. Unblinded content should require its own grant. Without that grant, the files, records and search results should stay hidden, whatever a person’s role. That last point is important. A viewer role should not become a side door to unblinded material, and a document search should not reveal a page that the user is not cleared to see. Ask how the workspace handles a user who has a study role but no unblinding grant, and ask what happens when the grant is added or removed.
Role changes, membership changes and unblinding changes should all appear in the append-only audit trail. The practical question is not only whether the platform records an action, but whether a study lead can reconstruct the sequence later. A clean access review depends on being able to see who had which role, for which study, and when that changed.
Check sign-in, session limits, and the demo questions that reveal gaps
Sign-in and session controls are easy to overlook because they sit outside the data view. They still belong on the checklist. Every sign-in should require an emailed code, and sessions should end after 30 minutes of inactivity. Ask whether that timeout applies to all users and whether an idle session can continue to view sensitive study material. Also ask how the emailed-code sign-in interacts with shared devices or a team member working from a conference room.
Ask also how the workspace handles a shared review session. If a team member leaves a screen open, the 30-minute inactivity timeout should cut off the session. If a study lead changes a role while someone is logged in, ask whether the change takes effect for the next access check. These are small operational questions, but they are the ones that reveal whether the controls are part of the daily workflow or only visible in a policy document.
Use a short list to keep the demo focused:
- Is each customer in a separate AWS account, with its own database and storage?
- Are records retired or superseded rather than deleted, with every file revision kept?
- Is the audit trail append-only, and does it cover membership, roles, unblinding and records?
- Are roles assigned by study, with distinct viewer, collaborator and owner permissions?
- Does unblinded content need its own grant, including in files, records and search results?
- Does every sign-in use an emailed code, and do sessions end after 30 minutes of inactivity?
A vendor’s answers should be specific enough to test. If a feature cannot be shown with a study record, treat it as an open item. The best time to resolve these questions is before the first data cut is loaded and before the study team has built its review habits around the workspace. A clinical trial data workspace should make secure access feel normal: study-level roles, clear unblinding grants, non-destructive records and a trail that holds up when someone asks how a decision was made.
Singapore fintech auditor biking through Buenos Aires. Wei Ling demystifies crypto regulation, tango biomechanics, and bullet-journal hacks. She roasts kopi luwak blends in hostel kitchens and codes compliance bots on sleeper buses.